Baromedical Nurses Association Standards

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Hyperbaric Oxygen Therapy (HBOT) treats conditions by increasing oxygen delivery to tissues, with the Undersea & Hyperbaric Medical Society (UHMS) listing 14 primary indications for its use UHMS Hyperbaric Oxygen Therapy Indications (14th Edition).
The UHMS maintains a comprehensive list of accepted indications, including air or gas embolism, where pulmonary barotrauma can occur from an ascent of as little as one meter after breathing compressed gas.
The FDA recommends UHMS-accredited facilities for specific HBOT treatments, ensuring quality and safety standards are met.
For conditions like air embolism, continuous intravenous infusion of oxygen at 10 mL/min has been tolerated in humans, while 20 mL/min caused symptoms, highlighting the precise nature of gas management.

Hyperbaric Oxygen Therapy (HBOT) is a medical treatment that involves breathing 100% oxygen in a pressurized environment. This method helps the body by dramatically increasing the amount of oxygen dissolved in the blood plasma, allowing more oxygen to reach tissues and organs that are deprived of it. The Undersea & Hyperbaric Medical Society (UHMS) serves as a key authority, defining and systematically reviewing the accepted indications for HBOT. Their detailed reports, such as the 14th Edition of "Hyperbaric Oxygen Therapy Indications," outline 14 specific conditions where this therapy is considered effective and appropriate UHMS Hyperbaric Oxygen Therapy Indications (14th Edition). For instance, in cases of air or gas embolism, which can occur from pulmonary barotrauma after an ascent of just one meter when breath-holding, HBOT plays a crucial role in managing the gas bubbles and supporting recovery. The UHMS also emphasizes the importance of accreditation for facilities providing HBOT, a recommendation supported by the FDA for specific illnesses, to ensure patient safety and treatment efficacy. See the arterial gas embolism evidence atlas for the full study-by-study evidence breakdown.

What is Hyperbaric Oxygen Therapy (HBOT)?

Hyperbaric Oxygen Therapy (HBOT) is a specialized medical treatment where a patient breathes pure, 100% oxygen inside a pressurized chamber. This chamber can be a single-person unit (monoplace) or a multi-person unit (multiplace), both designed to increase the atmospheric pressure around the patient. By combining increased pressure with a high concentration of oxygen, HBOT significantly boosts the amount of oxygen carried by the blood plasma, allowing it to reach areas of the body that might otherwise be oxygen-starved. This enhanced oxygen delivery helps to promote healing, fight infection, and reduce inflammation.

The Undersea and Hyperbaric Medical Society (UHMS) is a leading international organization dedicated to hyperbaric medicine. They play a critical role in defining what hyperbaric oxygen therapy is and in reviewing its various applications. The UHMS, headquartered at 631 US Highway 1, Suite 307, North Palm Beach, FL 33408, USA, publishes comprehensive reports, like their "Hyperbaric Oxygen Therapy Indications," which serves as the authoritative guide for healthcare professionals. These reports detail the accepted uses of HBOT, ensuring that the therapy is applied based on robust scientific evidence and clinical experience. The UHMS Hyperbaric Oxygen Therapy Committee is responsible for reviewing and accepting new indications for the therapy, ensuring that the list of approved treatments remains current and evidence-based.

The UHMS Definition of Hyperbaric Oxygen

The UHMS clearly defines hyperbaric oxygen as an intervention where a patient breathes 100% oxygen intermittently while inside a treatment chamber pressurized to greater than 1 atmosphere absolute (ATA). This definition distinguishes medical HBOT from other forms of oxygen delivery. The increased pressure allows more oxygen to dissolve into the body's fluids, including plasma, cerebrospinal fluid, and lymph, which can then reach tissues beyond the red blood cells' capacity. This mechanism is vital for treating conditions where oxygen delivery is compromised.

The Role of the Hyperbaric Oxygen Therapy Committee

The Hyperbaric Oxygen Therapy Committee is a cornerstone of the UHMS's work. This committee is composed of experts who rigorously evaluate scientific literature and clinical outcomes to determine which conditions are appropriate for HBOT. Their work culminates in the publication of the "Hyperbaric Oxygen Therapy Indications" report. Lindell K. Weaver MD, for example, served as Chair and Editor for the Thirteenth Edition of this crucial document, which was published by Best Publishing Company. The committee's ongoing review process ensures that only therapies with demonstrated efficacy are included, providing a reliable guide for practitioners. The UHMS explicitly states that "No responsibility is assumed by the Publisher or Editor for any injury and or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, product, instructions, or ideas contained in the material herein," emphasizing the need for independent clinical judgment in applying these guidelines. This statement, found in the preface of the Thirteenth Edition, underscores that while the indications are evidence-based, individual patient assessment remains paramount.

The Importance of Evidence-Based Indications

The UHMS's commitment to evidence-based medicine is reflected in its process for accepting new indications. Before a condition is added to the list, it undergoes thorough scrutiny by the Hyperbaric Oxygen Therapy Committee. This process involves evaluating research, clinical trials, and expert consensus to ensure that HBOT is a safe and effective treatment option. This systematic approach helps to standardize care and ensures that patients receive appropriate treatment for their specific conditions. The UHMS's dedication to this rigorous review process is fundamental to the credibility and medical acceptance of hyperbaric oxygen therapy. It is through this diligent work that the UHMS maintains its position as an authority in the field, guiding both practitioners and patients towards effective and safe treatment pathways.

What are the UHMS-Approved Indications for HBOT?

The Undersea & Hyperbaric Medical Society (UHMS) has established a comprehensive list of conditions for which Hyperbaric Oxygen Therapy (HBOT) is an approved treatment. This list is detailed in their "Hyperbaric Oxygen Therapy Indications" report, with the 14th Edition covering 14 distinct indications for treatment UHMS Hyperbaric Oxygen Therapy Indications (14th Edition). These indications are the result of extensive research and review by the UHMS Hyperbaric Oxygen Therapy Committee, ensuring that each approved use is backed by scientific evidence and clinical experience.

The Fourteen Primary Indications

The 14th Edition of the UHMS report outlines the following primary indications for HBOT, encompassing a range of acute and chronic conditions:

Air or Gas Embolism: This involves gas bubbles entering arteries or veins, which can be life-threatening. HBOT helps reduce bubble size and improves oxygenation.
Arterial Insufficiencies: This category includes:
- Central Retinal Artery Occlusion: A blockage of the main artery supplying blood to the retina, leading to sudden vision loss.
- Selected Problem Wounds: Chronic wounds that fail to heal with conventional treatment, such as diabetic foot ulcers.
Carbon Monoxide Poisoning: HBOT is crucial for displacing carbon monoxide from hemoglobin and improving oxygen delivery to tissues.
Clostridial Myonecrosis (Gas Gangrene): A severe bacterial infection that produces gas in tissues, requiring urgent intervention.
Compromised Grafts and Flaps: Tissues transplanted during surgery that are at risk of failure due to poor blood supply.
Acute Traumatic Ischemias: Conditions like crush injuries and compartment syndrome where blood flow to tissues is severely reduced.
Decompression Sickness: A diving-related injury caused by gas bubbles forming in the body due to rapid pressure changes.
Delayed Radiation Injuries (Soft Tissue and Bony Necrosis): Damage to tissues and bones that occurs months or years after radiation therapy.
Sudden Sensorineural Hearing Loss: A rapid loss of hearing, often without an identifiable cause.
Intracranial Abscess: A collection of pus within the brain, often requiring surgical drainage and antibiotics, with HBOT as an adjunct.
Necrotizing Soft Tissue Infections: Severe, rapidly spreading bacterial infections that destroy muscle, fat, and skin.
Refractory Osteomyelitis: A persistent bone infection that has not responded to standard antibiotic treatment.
Severe Anemia: In cases where a patient cannot receive blood transfusions, HBOT can provide enough oxygen to sustain life.
Adjunctive Hyperbaric Oxygen Therapy in the Treatment of Thermal Burns: Used alongside other treatments for severe burns to promote healing and reduce complications.

These indications highlight the diverse applications of HBOT, from immediate life-saving interventions for conditions like carbon monoxide poisoning and gas embolism to supportive therapy for chronic issues like problem wounds and delayed radiation injuries. Each indication has specific protocols and criteria for treatment, which are detailed further within the UHMS guidelines. See the carbon monoxide poisoning evidence atlas for the full study-by-study evidence breakdown.

Evolution of UHMS Indications

The UHMS regularly updates its "Hyperbaric Oxygen Therapy Indications" report to reflect the latest scientific understanding and clinical evidence. For example, the Thirteenth Edition also listed "Air or Gas Embolism," "Central Retinal Artery Occlusion," "Enhancement of Healing in Selected Problem Wounds," "Carbon Monoxide Poisoning," "Clostridial Myonecrosis (Gas Gangrene)," and "Compromised Grafts and Flaps" as key indications. The ongoing review process by the Hyperbaric Oxygen Therapy Committee ensures that the recommendations remain current and reliable. This commitment to continuous evaluation helps healthcare providers make informed decisions about when and how to use HBOT effectively and safely. The detailed table of contents in both the 13th and 14th editions demonstrates the structured approach taken by the UHMS to categorize and present these indications, making them accessible and understandable for medical professionals.

Importance of Adherence to Indications

Adhering to these UHMS-approved indications is critical for ensuring patient safety and treatment efficacy. HBOT is a powerful medical intervention, and like any medical procedure, it carries potential risks if not applied appropriately. By following the guidelines set forth by the UHMS, practitioners can confidently recommend and administer HBOT for conditions where it has been proven beneficial. This structured approach helps prevent the misuse of HBOT for unproven conditions, safeguarding both patients and the integrity of hyperbaric medicine. The UHMS's role in this regard is invaluable, providing a foundation for best practices in hyperbaric oxygen therapy globally.

How Does HBOT Treat Air or Gas Embolism?

Air or gas embolism is a critical medical emergency where gas bubbles enter the bloodstream, either in arteries or veins. This can lead to serious and life-threatening complications as these bubbles can block blood flow to vital organs. Hyperbaric Oxygen Therapy (HBOT) is a primary treatment for gas embolism because it effectively reduces the size of these gas bubbles and enhances oxygen delivery to tissues that are suffering from a lack of blood flow.

Richard E. Moon, in the "Hyperbaric Oxygen Therapy Indications: Air or Gas Embolism" section of the UHMS report, explains that "Gas embolism occurs when gas bubbles enter arteries or veins. Arterial gas embolism (AGE) was classically described during submarine escape training, in which pulmonary barotrauma occurred during free ascent after breathing compressed gas at depth." This highlights the historical context and severity of the condition. Pulmonary barotrauma and gas embolism can happen even from a small ascent, specifically, "after an ascent of as little as one meter" if breath-holding while breathing compressed gas. This shows how easily gas embolism can occur in various scenarios, not just extreme diving incidents UHMS Hyperbaric Oxygen Therapy Indications: Air or Gas Embolism.

Understanding Arterial Gas Embolism (AGE)

Arterial gas embolism (AGE) is particularly dangerous because bubbles in the arteries can travel to the brain, heart, or other critical organs, causing strokes, heart attacks, or other forms of tissue damage. Besides submarine escape training, AGE has been linked to normal ascent in divers with underlying lung conditions like bullous disease and asthma. Other causes of pulmonary barotrauma that can lead to AGE include blast injury (both in and out of water), mechanical ventilation, penetrating chest trauma, chest tube placement, and bronchoscopy. These diverse origins underscore the broad risk factors for AGE.

The mechanism by which HBOT helps AGE is twofold: first, the increased pressure in the hyperbaric chamber physically compresses the gas bubbles, reducing their size and allowing them to pass through blood vessels more easily. Second, breathing 100% oxygen at high pressure increases the partial pressure of oxygen in the blood significantly, helping to wash out the nitrogen or other inert gases from the bubbles and replace them with oxygen, which is then metabolized by the body. This process helps to resolve the embolism and re-oxygenate compromised tissues.

Understanding Venous Gas Embolism (VGE)

Venous gas embolism (VGE) is more common than AGE, especially after compressed gas diving. Normally, VGE bubbles are filtered and trapped by the pulmonary capillaries in the lungs and often do not cause clinical symptoms. However, if the volume of gas is large, VGE can overwhelm the lungs' capacity, leading to symptoms like cough, dyspnea (shortness of breath), and pulmonary edema. In severe cases, large volumes of VGE can even bypass the pulmonary capillaries, allowing bubbles to enter the arterial circulation, particularly if a patient has an atrial septal defect or patent foramen ovale (PFO), which are openings between the heart's chambers.

Causes of gas embolism beyond diving are numerous and include accidental intravenous air injection, cardiopulmonary bypass accidents during surgery, needle biopsy of the lung, hemodialysis, central venous catheter placement or disconnection, gastrointestinal endoscopy, and even hydrogen peroxide irrigation or ingestion. Surgical procedures where the site is under pressure, such as laparoscopy, transurethral surgery, vitrectomy, endoscopic vein harvesting, and hysteroscopy, can also lead to air embolism. Massive VGE can also occur when surgical wounds are elevated above the heart, creating a subatmospheric pressure in adjacent veins, allowing passive air entry. This has been observed in procedures like sitting craniotomy, cesarean sections, prostatectomy, spine surgery, hip replacement, liver resection, liver transplantation, and even dental implant insertion.

The Impact of Gas Volume

The volume of gas involved in an embolism significantly impacts the clinical outcome. Richard E. Moon notes that "Clinical deficits can occur after intra-arterial injection of only small volumes of air." In contrast, "Intravenous injection is often asymptomatic." Experimental animals have tolerated intravenous injections of up to 0.5-1 mL/kg. In humans, continuous IV infusion of oxygen at 10 mL/min has been reported as well tolerated, while 20 mL/min caused symptoms. This difference highlights the critical nature of even small arterial gas emboli and the body's varying tolerance to venous gas. Compared with constant infusions, injections of air are more likely to cause clinical abnormalities, emphasizing the acute danger of sudden gas entry. HBOT's ability to rapidly shrink bubbles and improve oxygenation makes it an essential and often life-saving intervention for both arterial and severe venous gas embolisms.

What Other Conditions Benefit from HBOT?

Beyond air and gas embolism, Hyperbaric Oxygen Therapy (HBOT) is an approved treatment for a wide array of conditions, as outlined by the Undersea & Hyperbaric Medical Society (UHMS). These conditions range from chronic wounds that resist healing to acute traumatic injuries and lingering effects of radiation therapy. The UHMS's 14th Edition of "Hyperbaric Oxygen Therapy Indications" provides detailed guidance on these diverse applications, underscoring HBOT's versatility in promoting healing and recovery across different medical specialties.

Enhancing Healing in Problem Wounds

One of the significant indications for HBOT is the enhancement of healing in selected problem wounds. These are typically chronic wounds that have not responded to conventional medical treatments over an extended period. A prime example is diabetic foot ulcers, which are a major complication of diabetes and can lead to severe infections and amputations if not properly managed. HBOT improves oxygen supply to the compromised tissues around these wounds, stimulating the growth of new blood vessels (angiogenesis), reducing inflammation, and enhancing the activity of white blood cells that fight infection. This boosted oxygen environment is crucial for the complex biological processes required for wound closure. The UHMS categorizes this under "Arterial Insufficiencies: Hyperbaric Oxygen Therapy for Selected Problem Wounds," highlighting its role in improving blood flow and tissue viability.

Treating Acute Traumatic Ischemias

Acute traumatic ischemias, such as crush injuries and compartment syndrome, represent another critical area where HBOT offers significant benefits. In these conditions, severe trauma leads to swelling and increased pressure within muscle compartments, cutting off blood supply (ischemia) to the tissues. Without rapid intervention, this lack of oxygen can result in permanent muscle damage, nerve damage, or even limb loss. HBOT helps by reducing swelling and inflammation, which in turn can alleviate pressure on blood vessels and restore blood flow. The high oxygen levels also provide immediate metabolic support to oxygen-deprived tissues, helping them to survive until normal circulation can be re-established. The UHMS outlines "The Role of Hyperbaric Oxygen for Acute Traumatic Ischemias" as a key indication, emphasizing its importance in limb salvage and functional recovery.

Addressing Delayed Radiation Injuries

Delayed radiation injuries, affecting both soft tissue and bony necrosis, are serious long-term complications that can arise months or even years after radiation therapy for cancer. Radiation can damage blood vessels and cells, leading to chronic non-healing wounds, bone death (osteonecrosis), and persistent pain. These tissues become hypoxic (oxygen-deprived) and struggle to repair themselves. HBOT works by promoting angiogenesis in the damaged areas, improving blood flow and oxygenation. This enhanced oxygen supply helps to repair damaged tissues, stimulate bone regeneration, and reduce pain. The UHMS recognizes "Delayed Radiation Injuries (Soft Tissue and Bony Necrosis) and Potential for Future Research" as a vital application, offering hope for patients suffering from these debilitating side effects.

Managing Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss (SSNHL) is an abrupt loss of hearing, typically in one ear, often without a clear cause. While corticosteroids are a common treatment, HBOT has emerged as an important adjunctive therapy. It is believed that SSNHL can be caused by a lack of oxygen to the inner ear structures or by inflammation. HBOT increases oxygen delivery to the inner ear, which can help to preserve and restore hearing function. The UHMS includes "Sudden Sensorineural Hearing Loss" as one of its approved indications, pointing to the evidence supporting its use in improving outcomes for this condition.

Combating Refractory Osteomyelitis

Refractory osteomyelitis is a persistent and chronic bone infection that has failed to respond to standard treatments, including prolonged courses of antibiotics and surgical debridement. These infections are challenging because bacteria can form biofilms that are difficult for antibiotics to penetrate, and the infected bone often has poor blood supply, limiting the delivery of both antibiotics and oxygen. HBOT addresses this by significantly increasing tissue oxygen levels, which enhances the killing power of certain antibiotics, improves the function of infection-fighting white blood cells, and promotes the growth of new blood vessels and bone formation. This multi-faceted approach makes HBOT a valuable tool in resolving stubborn bone infections. The UHMS lists "Refractory Osteomyelitis" as an indication, acknowledging its role in achieving successful outcomes where other treatments have failed. For more details, see FDA recommendations for UHMS-accredited facilities.

Other Important Indications

The UHMS also approves HBOT for several other critical conditions, including:

Carbon Monoxide Poisoning: HBOT helps to quickly clear carbon monoxide from the body and prevent neurological damage.
Clostridial Myonecrosis (Gas Gangrene): It inhibits the growth of anaerobic bacteria and neutralizes toxins.
Compromised Grafts and Flaps: HBOT improves the survival rate of transplanted tissues by enhancing oxygen delivery.
Intracranial Abscess: It serves as an adjunct to antibiotics and surgery, improving oxygenation in infected brain tissue.
Necrotizing Soft Tissue Infections: HBOT helps to stop the spread of these aggressive infections and supports tissue healing.
Severe Anemia: In cases where blood transfusions are not possible or contraindicated, HBOT can provide life-sustaining oxygen.
Adjunctive Hyperbaric Oxygen Therapy in the Treatment of Thermal Burns: It reduces swelling, promotes wound healing, and lessens the need for surgery in severe burn cases.

These diverse indications demonstrate HBOT's broad therapeutic potential when applied according to the rigorous standards set by the UHMS. Each condition benefits from the fundamental principle of HBOT: saturating the body with oxygen to support healing and recovery processes that are otherwise hindered by oxygen deficiency.

Why is Accreditation Important for HBOT Facilities?

Accreditation for Hyperbaric Oxygen Therapy (HBOT) facilities is critically important because it ensures that clinics meet rigorous standards for patient safety, quality of care, and proper operational procedures. The U.S. Food & Drug Administration (FDA) itself recommends UHMS-accredited hyperbaric facilities for the treatment of specific illnesses. This recommendation from a federal agency like the FDA underscores the significance of accreditation in the safe and effective delivery of HBOT. When a facility is accredited, it signifies that it has undergone a thorough evaluation by an independent body, confirming its adherence to established best practices in hyperbaric medicine.

The Undersea & Hyperbaric Medical Society (UHMS) operates a comprehensive Hyperbaric Facility Accreditation Program. This program is designed to assess and certify facilities based on strict guidelines that cover everything from equipment maintenance and staff training to emergency protocols and patient management. Accreditation is not a one-time event; it involves regular reviews and updates to ensure ongoing compliance with evolving standards. This continuous oversight is vital in a specialized field like hyperbaric medicine, where patient safety is paramount due to the unique environment of a hyperbaric chamber.

Ensuring Patient Safety and Quality of Care

Accreditation directly contributes to patient safety by enforcing strict protocols for chamber operation, oxygen administration, and emergency response. For example, hyperbaric chambers, whether monoplace (for one patient) or multiplace (for multiple patients), must be maintained to specific safety standards to prevent mechanical failures or oxygen-related hazards. The FDA maintains a 510(k) Premarket Notification system, which is part of its oversight for medical devices, including hyperbaric chambers, further emphasizing the need for regulatory compliance and safety in their design and operation. While specific details of a 510(k) notification like "k021690" relate to individual device clearances, the broader regulatory environment necessitates that facilities use approved and well-maintained equipment.

Furthermore, accredited facilities must have highly trained personnel, including physicians, nurses, and technicians, who are knowledgeable in hyperbaric medicine. This training covers not only the technical aspects of operating a hyperbaric chamber but also the medical management of patients undergoing HBOT, including recognizing and managing potential side effects or complications. The UHMS provides resources like "Introductory 40-Hour Training Courses" and an "Online Continuing Education Portal" to support the ongoing education of hyperbaric professionals, ensuring that staff in accredited facilities are well-prepared to deliver high-quality care.

Meeting Regulatory and Professional Standards

Accreditation serves as a benchmark for professional excellence in hyperbaric medicine. It demonstrates a facility's commitment to adhering to the highest standards of care as defined by the leading professional organization in the field, the UHMS. This compliance helps facilities meet regulatory requirements and often influences insurance coverage decisions, as many payers prefer or require treatment at accredited centers. The "Utilization Review For Hyperbaric Oxygen Therapy" section in the UHMS's 13th and 14th Editions of the Indications report underscores the importance of proper utilization, which is implicitly supported by accreditation. The preface of the UHMS Thirteenth Edition emphasizes the responsibility of practitioners, stating, "No suggested test or procedure should be carried out unless, in the reader’s judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages be made." This reinforces the need for competent and accredited facilities to make such judgments.

The FDA's recommendation for UHMS-accredited facilities is a powerful endorsement. It signals to both patients and healthcare providers that these facilities are recognized for their commitment to providing safe and effective hyperbaric oxygen therapy for the approved indications. This public recommendation helps patients make informed choices about where to seek treatment, knowing that accredited centers have met stringent criteria for both operational safety and clinical competence. Without such accreditation, there is a higher risk of inconsistent care, equipment malfunctions, or treatments being administered by inadequately trained staff, all of which could compromise patient outcomes.

The UHMS Accreditation Process

The UHMS offers resources like "How to Prepare for Accreditation Workshop" to guide facilities through the accreditation process. This process typically involves a detailed review of the facility's policies and procedures, on-site inspections, and interviews with staff members. Facilities are evaluated on various aspects, including:

Chamber Operations: Safety checks, maintenance logs, and emergency protocols.
Medical Staff Qualifications: Credentials, training, and continuing education.
Patient Care Protocols: Adherence to UHMS-approved indications, patient assessment, and treatment planning.
Quality Assurance Programs: Systems for monitoring and improving care.
Emergency Preparedness: Ability to handle medical emergencies within the hyperbaric environment.

By achieving and maintaining UHMS accreditation, facilities not only uphold a high standard of care but also contribute to the overall credibility and advancement of hyperbaric medicine. This commitment ensures that patients receive the best possible treatment in a safe and controlled environment, reinforcing the trust placed in HBOT as a valuable medical therapy.

Who are the Experts Behind UHMS Indications?

The authority and reliability of the Undersea & Hyperbaric Medical Society (UHMS) indications for Hyperbaric Oxygen Therapy (HBOT) stem directly from the expertise of its Hyperbaric Oxygen Therapy Committee. This dedicated group of professionals is responsible for the rigorous review, evaluation, and acceptance of new indications for HBOT, ensuring that all recommendations are grounded in robust scientific evidence and clinical experience. Their work is crucial in maintaining the credibility and safety standards of hyperbaric medicine.

The Hyperbaric Oxygen Therapy Committee

The Hyperbaric Oxygen Therapy Committee is the core group that drives the UHMS's mission to define and promote best practices in HBOT. Members of this committee are typically highly experienced physicians, researchers, and other healthcare professionals specializing in hyperbaric and diving medicine. Their collective knowledge spans various medical disciplines, allowing for a comprehensive evaluation of HBOT's efficacy and safety across a wide range of conditions. This interdisciplinary approach is essential because HBOT has applications in areas such as wound care, infectious diseases, neurological conditions, and emergency medicine.

The committee's responsibilities include:

Reviewing Scientific Literature: Systematically analyzing published research, clinical trials, and case studies related to HBOT.
Evaluating Clinical Outcomes: Assessing the effectiveness of HBOT in real-world clinical settings.
Developing and Updating Guidelines: Creating and refining the "Hyperbaric Oxygen Therapy Indications" report, which serves as the authoritative guide for the field.
Accepting New Indications: Establishing clear criteria and a rigorous process for adding new conditions to the list of approved HBOT treatments.

This structured approach ensures that any condition listed as a UHMS-approved indication has undergone thorough scrutiny and is supported by a strong evidence base.

Leadership and Editorship

The leadership within the Hyperbaric Oxygen Therapy Committee is vital for guiding its work. For instance, Lindell K. Weaver MD served as the Chair and Editor for the Thirteenth Edition of the "Hyperbaric Oxygen Therapy Indications" report. As Chair and Editor, Dr. Weaver played a pivotal role in organizing the committee's efforts, synthesizing complex information, and ensuring the clarity and accuracy of the published guidelines. The title of "Chair and Editor" signifies a significant responsibility in curating and presenting the collective knowledge and consensus of the committee to the broader medical community.

The UHMS reports, such as the 13th and 14th Editions, are comprehensive documents that include not only the list of indications but also background information, definitions of HBOT, details on utilization review, and biographies of the authors. This transparency allows readers to understand the expertise behind the recommendations. The "Author Biographies" section in these reports provides insights into the qualifications and experience of the individuals who contribute to these critical documents, further solidifying the credibility of the UHMS indications. These individuals are often recognized leaders in their respective fields, bringing a wealth of clinical experience and research acumen to the committee's deliberations.

Ensuring Evidence-Based Recommendations

The core principle guiding the Hyperbaric Oxygen Therapy Committee is the commitment to evidence-based medicine. This means that every claim and recommendation regarding HBOT's efficacy must be supported by verifiable data. The committee does not rely on anecdotal evidence or unproven theories. Instead, it meticulously examines the scientific literature, considering the strength of evidence from randomized controlled trials, systematic reviews, and meta-analyses. This rigorous approach is crucial for several reasons:

Patient Safety: It ensures that patients receive treatments that are proven to be safe and effective, minimizing risks.
Clinical Efficacy: It helps practitioners make informed decisions about when and how to use HBOT for optimal patient outcomes.
Medical Acceptance: It builds trust and acceptance within the broader medical community, facilitating the integration of HBOT into mainstream healthcare.
Resource Allocation: It guides healthcare systems and insurance providers in allocating resources for HBOT, ensuring that it is used for appropriate conditions.

The UHMS's dedication to this rigorous, evidence-based process is what makes its "Hyperbaric Oxygen Therapy Indications" the gold standard in the field. The preface of the Thirteenth Edition clearly states, "No responsibility is assumed by the Publisher or Editor for any injury and or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, product, instructions, or ideas contained in the material herein." It further advises, "No suggested test or procedure should be carried out unless, in the reader’s judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that the independent verification of diagnoses and drug dosages be made." This emphasizes that while the committee provides expert guidance, individual clinicians must still exercise their professional judgment and stay updated on medical advances.

By entrusting the development of these crucial guidelines to a committee of highly qualified experts, the UHMS ensures that its recommendations are not only scientifically sound but also practical and relevant for clinicians providing hyperbaric oxygen therapy.

Frequently Asked Questions

What is the Undersea & Hyperbaric Medical Society (UHMS)?

The Undersea & Hyperbaric Medical Society (UHMS) is a leading international non-profit organization dedicated to advancing undersea and hyperbaric medicine. It is based at 631 US Highway 1, Suite 307, North Palm Beach, FL 33408, USA. The UHMS plays a critical role in defining hyperbaric oxygen therapy, reviewing its indications, and accrediting facilities to ensure high standards of care. Their Hyperbaric Oxygen Therapy Committee publishes comprehensive reports that guide medical professionals on the safe and effective use of HBOT.

How many conditions are approved for HBOT by UHMS?

The UHMS has approved 14 primary indications for Hyperbaric Oxygen Therapy (HBOT). These are detailed in their "Hyperbaric Oxygen Therapy Indications," 14th Edition. This comprehensive list includes conditions such as air or gas embolism, carbon monoxide poisoning, severe anemia, and delayed radiation injuries, among others. Each indication has undergone rigorous review by the UHMS Hyperbaric Oxygen Therapy Committee to ensure its efficacy and safety.

Can HBOT treat carbon monoxide poisoning?

Yes, Hyperbaric Oxygen Therapy (HBOT) is an approved indication for carbon monoxide poisoning. It is listed as one of the 14 primary indications in the UHMS's 14th Edition of "Hyperbaric Oxygen Therapy Indications." HBOT is highly effective in treating carbon monoxide poisoning because the increased pressure and 100% oxygen help to rapidly remove carbon monoxide from the hemoglobin in red blood cells, replacing it with oxygen and preventing further damage to tissues and organs, particularly the brain.

Is HBOT recommended for diving-related injuries?

Yes, HBOT is specifically recommended for diving-related injuries, most notably decompression sickness and air or gas embolism. Decompression sickness, often referred to as "the bends," occurs when gas bubbles form in the body due to rapid changes in pressure during or after a dive. Air or gas embolism, which can result from pulmonary barotrauma during ascent, can occur from an ascent of as little as one meter after breathing compressed gas while breath-holding. HBOT helps to reduce the size of these gas bubbles and improve oxygenation to affected tissues.

Why does the FDA recommend UHMS-accredited facilities?

The FDA recommends UHMS-accredited hyperbaric facilities for treating specific illnesses because accreditation ensures that these facilities meet rigorous safety and quality standards. The UHMS Hyperbaric Facility Accreditation Program evaluates aspects such as equipment maintenance, staff training, and emergency protocols. This recommendation helps assure patients and healthcare providers that accredited centers adhere to best practices, ensuring safe and effective delivery of hyperbaric oxygen therapy.